Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pamela Daher

Colon & Rectal Surgery Galveston, TX Medical Doctor

NPI 1588083984 CMS profile 920763

1005 Harborside Dr 5Th Floor, Galveston, TX 77555

Open in the dashboard

General payments

$14,016

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Daher of Galveston, TX is reported in the CMS Open Payments database as having received $14,016 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $167 3
2024 General $1,148 12
2023 General $4,527 11
2021 General $4,502 9
2020 General $3,172 3
2019 General $499 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Daher
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Pamela Daher were reported at $167. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Pamela Daher Colon & Rectal Surgery median Middle half National median
2019 $499 $443 $125–$2,179 $163
2020 $3,172 $167 $53–$931 $114
2021 $4,502 $207 $72–$1,272 $132
2022 $0 $341 $111–$1,587 $149
2023 $4,527 $322 $115–$1,420 $160
2024 $1,148 $328 $112–$1,354 $164
2025 $167 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $11,414 17 payments
  2. THD America, Inc. $1,643 9 payments
  3. Stryker Corporation $486 2 payments
  4. Baxter Healthcare $121 1 payment
  5. Hollister Incorporated $115 1 payment
  6. Medtronic, Inc. $88 4 payments
  7. AstraZeneca Pharmaceuticals LP $35 1 payment
  8. Merck Sharp & Dohme Corporation $34 3 payments
  9. Boston Scientific Corporation $30 2 payments
  10. Braintree Laboratories, Inc. $21 1 payment
  11. Other $28 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $10,360 6 payments
  2. Food and Beverage $1,913 31 payments
  3. Travel and Lodging $1,735 6 payments
  4. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System Surgery $4,414 14 payments
  2. Da Vinci Surgical System Surgery $4,000 2 payments
  3. DAVINCI XI $3,000 1 payment
  4. None $325 1 payment
  5. SPY TECHNOLOGY $161 1 payment
  6. No Related Product $121 1 payment
  7. New Image $115 1 payment
  8. INTERSTIM $88 4 payments
  9. IMFINZI $35 1 payment
  10. BRIDION $34 3 payments
  11. Other $177 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

144

Median for Colorectal Surgery (Proctology): 106

Drug cost

$14,124

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

36.8%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Motegrity Prucalopride Succinate Brand 19 $13,202
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $282
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 12 $204
Gabapentin Generic 27 $156
Neomycin Sulfate Generic 21 $123
Metronidazole Generic 25 $117
Tramadol Hcl Generic 18 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$21,871

Medicare's payments for the services billed

Medicare patients

85

Average age 72

Services billed

199

46 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 32%
Diabetes 28%
Heart failure 27%
Chronic kidney disease 27%
COPD 25%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record